Merck and Moderna's Cancer Vaccine Succeeds in Phase 3

A personalized mRNA cancer vaccine from Merck and Moderna has succeeded in Phase 3 trials, marking a major breakthrough in immunotherapy.

The treatment, called intismeran autogene, tailors cancer-fighting instructions to each patient's unique tumor.